Table 3.
Association of differentiation phenotypes with response in clinical trials.
| Cancer | Differentiation phenotype | Corresponding subtype | Association with response | Reference |
|---|---|---|---|---|
| Melanoma | CD27+ | Tscm and Tcm | Unsubstantial | (6) |
| Melanoma | CD28+ | All | Unsubstantial | (6) |
| Melanoma | CD45RA+ | Tscm, Teff and Temra | Unsubstantial | (6) |
| Melanoma | CD45RO+ | Tcm and Tem | Unsubstantial | (6) |
| Neuroblastoma | CD45RO+CD62L+ | Tcm | Phenotype percentage - CAR-T persistence (p ≤ 0.055), CAR-T persistence – TTP (p=0.02) | (7) |
| Melanoma | CD8+CD27+ | Tn, Tscm and Tcm | CR vs. (PR+NR) p=0.001, (CR+PR) vs. NR p<0.001 | (9) |
| Biliary tract cancer | CD45RO+CD62L+CCR7+ | Tcm | CR/SD vs. PD, p=0.0464 | (10) |
| Chronic lymphocytic leukemia | CD8+CD27+CD45RO- | Tscm | CR/PRTD vs. PR/NR p=0.0009 | (5) |
| Chronic lymphocytic leukemia | CD8+CD45RO-CCR7+CD45RA+CD62L+CD27+CD28+IL7Rα+CD95+ | CD8+ Tscm | CR vs. NR p=0.0008, CR/PRTD vs. PR/NR p=0.0055, CR vs. PR p=0.0121 | (5) |
| Multiple myeloma | CD8+CD45RO-CD27+ | Tscm | ≥PR vs. <PR, p=0.0121 | (8) |
| Pancreatic carcinoma | CD45RO+CD62L+CCR7+ | Tcm | PR/SD vs. PD p=0.0468 | (11) |
| Melanoma | CD8+CD39-CD69- | Stem-like CD8 T cells | CR vs. NR, p<0.01 | (100) |
| Melanoma | CD39-CD69- | Stem-like T cells | CR vs. NR, p=0.0096 | (100) |
| LBCL | CD8+CCR7+CD27+ | CD8+ Tscm and Tcm | CR vs. PR/PD, p<2.2×10-16 | (101) |